FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2523641513> ?p ?o ?g. }

• W2523641513 abstract "Abstract In addition to therapeutic efficacy in imatinib-resistant BCR-ABL positive malignancies, dasatinib may have off-target immunomodulatory effects by inhibiting kinases (e.g. SRCs, c-KIT) in immune effector cells. In a proportion of patients, dasatinib treatment is associated with non-infectious pleural effusions and panniculitis, which may reflect aberrant immune reactivity. Here we describe a marked expansion of clonal LGL lymphocytes in blood among 11 BCR-ABL positive patients on dasatinib therapy (5 CML CP, 1 CML AP, 1 CML BC, 4 Ph+ALL). All patients were previously exposed to imatinib without similar changes in lymphocyte count or morphology. The median time to LGL lymphocytosis was 2 months from the start of dasatinib (range 1–8 months). It developed abruptly, with a peak lymphocyte count of 4–20 ×109/L, and was often preceded by low-grade fever. In all evaluable cases, lymphocyte counts normalized after drug discontinuation. By immunophenotyping, 6 patients had a CD3/CD8+ cytotoxic T-cell phenotype and 4 patients had a CD56+ NK-cell phenotype. The LGL lymphocytes were BCR-ABL negative. All CD3-positive cases had a clonal rearrangement of TCR gamma/delta genes by PCR; clonality was not detected in samples prior to dasatinib therapy (n=3). In TCR beta gene repertoire assay, oligoclonal patterns were seen in selected genes. All patients with HLA data had the A2 allele (n=8). Dasatinib-related complications were common: pleural effusions and/or pulmonary infiltrates (n=8), modest CMV reactivation (n=5), severe colitis (n=5), which developed after appearance of LGL lymphocytosis. Immunophenotyping was available from 2 patients with pleural effusions: in both cases the majority of cells were CD3+CD8+ T-cells and no leukemic cells were detected. TCR gamma assay was done from one patient sample and it showed similar clonal pattern as in peripheral blood. However, despite frequent side-effects, response to dasatinib treatment was very good in all cases, including complete molecular responses in 5 advanced phase patients. Transient clonal LGL lymphocytosis has been described in few patient cases with a primary herpesvirus infection. Our patients share striking pheno/genotypic similarities with LGL leukemia, in which an antigen driven expansion of LGLs precedes the occurrence of oncogenic events. However, in our patients LGL lymphocytosis appeared to be a benign phenomenon. We postulate that by virtue of inhibition of key non-BCR-ABL kinases, dasatinib induces a reversible state of autoimmune-like reactivity upon antigen challenge in a proportion of patients with a distinct genetic and/or environmental background. The aberrant immune response may also result in enhanced anti-leukemic control driven by the cytotoxic T/NK LGL cells. Dasatinib could be a valuable tool in uncovering the pathogenesis of LGL lymphoproliferation, putatively related to mutations in kinases targeted by the drug." @default.
• W2523641513 created "2016-09-30" @default.
• W2523641513 creator A5001854188 @default.
• W2523641513 creator A5002063554 @default.
• W2523641513 creator A5002679205 @default.
• W2523641513 creator A5004083002 @default.
• W2523641513 creator A5008868111 @default.
• W2523641513 creator A5014402272 @default.
• W2523641513 creator A5015115182 @default.
• W2523641513 creator A5015214215 @default.
• W2523641513 creator A5023652212 @default.
• W2523641513 creator A5023781653 @default.
• W2523641513 creator A5028022318 @default.
• W2523641513 creator A5033314197 @default.
• W2523641513 creator A5038000746 @default.
• W2523641513 creator A5050873337 @default.
• W2523641513 creator A5051537989 @default.
• W2523641513 creator A5062230211 @default.
• W2523641513 creator A5075849003 @default.
• W2523641513 creator A5086793834 @default.
• W2523641513 creator A5089054933 @default.
• W2523641513 date "2007-11-16" @default.
• W2523641513 modified "2023-09-26" @default.
• W2523641513 title "Clonal Large Granular Lymphocyte (LGL) Expansion Associated with Dasatinib Therapy." @default.
• W2523641513 doi "https://doi.org/10.1182/blood.v110.11.2938.2938" @default.
• W2523641513 hasPublicationYear "2007" @default.
• W2523641513 type Work @default.
• W2523641513 sameAs 2523641513 @default.
• W2523641513 citedByCount "4" @default.
• W2523641513 countsByYear W25236415132018 @default.
• W2523641513 crossrefType "journal-article" @default.
• W2523641513 hasAuthorship W2523641513A5001854188 @default.
• W2523641513 hasAuthorship W2523641513A5002063554 @default.
• W2523641513 hasAuthorship W2523641513A5002679205 @default.
• W2523641513 hasAuthorship W2523641513A5004083002 @default.
• W2523641513 hasAuthorship W2523641513A5008868111 @default.
• W2523641513 hasAuthorship W2523641513A5014402272 @default.
• W2523641513 hasAuthorship W2523641513A5015115182 @default.
• W2523641513 hasAuthorship W2523641513A5015214215 @default.
• W2523641513 hasAuthorship W2523641513A5023652212 @default.
• W2523641513 hasAuthorship W2523641513A5023781653 @default.
• W2523641513 hasAuthorship W2523641513A5028022318 @default.
• W2523641513 hasAuthorship W2523641513A5033314197 @default.
• W2523641513 hasAuthorship W2523641513A5038000746 @default.
• W2523641513 hasAuthorship W2523641513A5050873337 @default.
• W2523641513 hasAuthorship W2523641513A5051537989 @default.
• W2523641513 hasAuthorship W2523641513A5062230211 @default.
• W2523641513 hasAuthorship W2523641513A5075849003 @default.
• W2523641513 hasAuthorship W2523641513A5086793834 @default.
• W2523641513 hasAuthorship W2523641513A5089054933 @default.
• W2523641513 hasConcept C147483822 @default.
• W2523641513 hasConcept C167672396 @default.
• W2523641513 hasConcept C196166836 @default.
• W2523641513 hasConcept C203014093 @default.
• W2523641513 hasConcept C2777583451 @default.
• W2523641513 hasConcept C2777761686 @default.
• W2523641513 hasConcept C2778729363 @default.
• W2523641513 hasConcept C2779536868 @default.
• W2523641513 hasConcept C2780126324 @default.
• W2523641513 hasConcept C3019892230 @default.
• W2523641513 hasConcept C71924100 @default.
• W2523641513 hasConcept C86803240 @default.
• W2523641513 hasConcept C8891405 @default.
• W2523641513 hasConceptScore W2523641513C147483822 @default.
• W2523641513 hasConceptScore W2523641513C167672396 @default.
• W2523641513 hasConceptScore W2523641513C196166836 @default.
• W2523641513 hasConceptScore W2523641513C203014093 @default.
• W2523641513 hasConceptScore W2523641513C2777583451 @default.
• W2523641513 hasConceptScore W2523641513C2777761686 @default.
• W2523641513 hasConceptScore W2523641513C2778729363 @default.
• W2523641513 hasConceptScore W2523641513C2779536868 @default.
• W2523641513 hasConceptScore W2523641513C2780126324 @default.
• W2523641513 hasConceptScore W2523641513C3019892230 @default.
• W2523641513 hasConceptScore W2523641513C71924100 @default.
• W2523641513 hasConceptScore W2523641513C86803240 @default.
• W2523641513 hasConceptScore W2523641513C8891405 @default.
• W2523641513 hasLocation W25236415131 @default.
• W2523641513 hasOpenAccess W2523641513 @default.
• W2523641513 hasPrimaryLocation W25236415131 @default.
• W2523641513 hasRelatedWork W2029556274 @default.
• W2523641513 hasRelatedWork W2073035156 @default.
• W2523641513 hasRelatedWork W2248201536 @default.
• W2523641513 hasRelatedWork W2310036617 @default.
• W2523641513 hasRelatedWork W2523641513 @default.
• W2523641513 hasRelatedWork W2567894154 @default.
• W2523641513 hasRelatedWork W2574864779 @default.
• W2523641513 hasRelatedWork W2590322037 @default.
• W2523641513 hasRelatedWork W2979367715 @default.
• W2523641513 hasRelatedWork W2739704174 @default.
• W2523641513 isParatext "false" @default.
• W2523641513 isRetracted "false" @default.
• W2523641513 magId "2523641513" @default.
• W2523641513 workType "article" @default.